AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study ResultsZacks Investment Research • 11/20/25
Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease TranscriptSeeking Alpha • 11/19/25
Agios Pharma reports mixed results in late-stage study for sickle cell disease drugReuters • 11/19/25
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell DiseaseGlobeNewsWire • 11/19/25
Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA MilestonesSeeking Alpha • 11/04/25
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and ExpositionGlobeNewsWire • 11/03/25
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y RevenuesZacks Investment Research • 10/31/25
Agios Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 10/30/25
Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with ThalassemiaBusiness Wire • 10/17/25
Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with ThalassemiaGlobeNewsWire • 10/17/25
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ETGlobeNewsWire • 10/16/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIOGlobeNewsWire • 09/24/25
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law FirmPRNewsWire • 09/18/25
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law FirmBusiness Wire • 09/15/25
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for ThalassemiaZacks Investment Research • 09/05/25
Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be MitigatedSeeking Alpha • 09/04/25
FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded UseBenzinga • 09/04/25
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in ThalassemiaGlobeNewsWire • 09/04/25
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi ArabiaGlobeNewsWire • 08/04/25